On March 13, 2025, the much-anticipated BIOCHINA 2025 (10th) International Convention kicked off at the Suzhou International Expo Center. The results of the BIOCHINA Awards 2024 were grandly announced at this expo. Shanghai Escugen Biotechnology Co., Ltd. was honored to be listed on the BIOCHINA Awards 2024 —— "Top 100 Innovative Breakthrough Enterprises" for its outstanding performance and great potential in the bio-pharmaceutical innovation and research field. This award is not only a high recognition of Escugen's innovative breakthrough capabilities and achievements in the past, but also an incentive and expectation for its continued innovation in the future.

The BIOCHINA International Convention attracted over 30,000 participants, with  more than 400 exhibitors from home and abroad and over 300 international representatives attending, covering 28 overseas countries and regions. The BIOCHINA Awards 2024 selection activity attracted the active participation of many outstanding bio-enterprises from all over the country. The award was jointly organized by the BIOCHINA Organizing Committee and a professional evaluation committee, adhering to the principles of fairness, justice, and openness, and comprehensively assessed and selected through multi-dimensional real data. The final selection of the top 100 most innovative and breakthrough enterprises from numerous outstanding candidates. As an annual evaluation with extensive influence in the bio-industry, BIOCHINA Awards has gone through nine years and has become an important platform for discovering innovative forces in the bio-industry and promoting industrial innovation and development.

Dr. Zhou Qing, the co-founder and CEO of Escugen, said at the award ceremony: "Winning this prestigious award is the greatest encouragement for the Escugen team's long-term relentless pursuit of innovation. We are well aware that the path of bio-pharmaceutical research and development is full of challenges, but it is precisely these challenges that have inspired our continuous courage and determination to break through. This honor belongs to every Escugen person. It is the result of everyone's joint efforts and in-depth research. Standing at this new milestone, Escugen will continue to focus on the innovation and research of bio-pharmaceuticals, guided by patient needs, accelerate the progress of pipeline products, and strive to become an important member of the global bio-industry innovation map."